SAE, serious adverse event

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, Indalecio Monteagudo-Sáez, Michel Malaise, Athanasios G Tzioufas, Johannes W J Bijlsma, Kristina Unnebrink, Sonja Kary, Hartmut Kupper

Annals of the Rheumatic Diseases Jun 2007, 66 (6) 732-739; DOI: 10.1136/ard.2006.066761
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
Michael Weinblatt, Michael Schiff, Allan Goldman, Joel Kremer, Michael Luggen, Tracy Li, Dalei Chen, Jean-Claude Becker

Annals of the Rheumatic Diseases Feb 2007, 66 (2) 228-234; DOI: 10.1136/ard.2006.055111
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 889-894; DOI: 10.1136/ard.2005.043166

Main menu